ClinicalTrials.gg
Active, not recruitingNCT07861542Updated Nov 12, 2026

Study of a Recombinant Spike COVID-19 Vaccine With Matrix-M in Older Adults and People at Increased Risk of Severe COVID-19

A Phase 4 interventional study of Omicron Subvariant-Based SARS-CoV-2 Recombinant Spike Vaccine Adjuvanted With Matrix-M in COVID-19, sponsored by Sanofi. Active, not recruiting at 20 sites in United States. Open to participants aged 12 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-11-12.

Sponsored by Sanofi · Phase 4, Interventional, and Prevention

Updated Nov 12, 2026Now Active, not recruitingNow Recruiting+5 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
669
Allocation
Not applicable
Ages
12 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 18 studies testing NVX-CoV2373 adjuvated lipid nanoparticle in COVID-19 — none open to participants now, 2 under way, none of them phase 3. NVX-CoV2373 adjuvated lipid nanoparticle · COVID-19.

Enrollment
12th of 18
669 · median 997
Started
2026
the only one that year
Phase 4
5 of 18
none open now
Registered
18th of 18
by date
Lead sponsor
1 of 18
Sanofi

Among the 18 studies testing NVX-CoV2373 adjuvated lipid nanoparticle in COVID-19, this one is the 12th largest by enrollment, is the only one that started in 2026, is one of 5 in phase 4, and was the 18th registered.

COVID-19

7,994 studies on the registry are indexed under COVID-19; 468 are open to participants now.

Browse COVID-19 studies →

Open to participants now

None of the 18 studies testing NVX-CoV2373 adjuvated lipid nanoparticle in COVID-19 is open now. The open studies under COVID-19, anywhere →

About NVX-CoV2373 adjuvated lipid nanoparticle

No approval found in the FDA or EMA files read. How studies give it is on its page →

Who these studies take

Of the 356 COVID-19 studies recruiting now, 206 (58%) set no upper age limit and 83 (23%) stop at 75 or younger; 91 take children under 18; 135 take healthy volunteers.

This study: 12 Years and older · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 18 studies testing NVX-CoV2373 adjuvated lipid nanoparticle in COVID-19 as a file.
02

Study summary

The purpose of this study is to evaluate the safety and immunogenicity of a single dose of Sanofi's Omicron subvariant-based Nuvaxovid in participants ≥ 65 years of age and participants 12 through 64 years of age who have at least one underlying condition that puts them at increased risk for severe outcomes of COVID-19 and who have been previously vaccinated with a COVID-19 vaccine ≥ 90 days prior to study vaccination.

Study details include:

  • The study duration will be approximately 3 months per participant.
  • Study intervention will be administered via a single intramuscular (IM) injection into the deltoid muscle on Day 1.
  • The visit frequency will be Day 1, Day 9 telephone call, Day 29, and Day 91 telephone call (3-month safety follow-up).
03

Conditions studied

  • COVID-19

Browse trials for

Keywords

  • NUVAXOVID
  • COVID-19
  • SARS-CoV-2 Infection
04

Who can participate

Ages eligible
12 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

To be included in this study, each individual must satisfy all the following criteria:

  • Participants ≥ 65 years of age, or participants 12 through 64 years of age who have at least 1 underlying condition that puts them at increased risk for severe outcomes from COVID-19 at the time of study vaccination.
  • Previously vaccinated with a COVID-19 vaccine, with the last dose administered ≥ 90 days prior to study vaccination.
  • Participants must not be pregnant or breastfeeding. Participants of must have a negative highly sensitive pregnancy test at enrollment and must agree to use an effective method of or remain abstinent from ≥ 4 weeks before study vaccination through ≥ 4 weeks after vaccination.

Exclusion criteria

Exclusion Criteria:

Participants are not eligible if any of the following criteria are met:

  • Known or suspected congenital or acquired immunodeficiency; receipt of therapy, such as anti-cancer chemotherapy or radiation therapy, within the past 6 months; or long-term use of systemic .
  • History of virologically confirmed SARS-CoV-2 infection within 90 days before study vaccination.
  • Known systemic to any component of the study intervention or a history of a life-threatening reaction to the study intervention or to a product containing the same substances.
  • Prior history of myocarditis, pericarditis, or myopericarditis.
  • Receipt of any vaccine within 28 days before study vaccination, except for influenza vaccine, which may be administered at least 14 days before study vaccination.
  • Receipt of an or marketed COVID-19 vaccine within 90 days before study vaccination.

The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.

Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 4
Primary purpose
Prevention
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
669 participants (actual)

Study arms

  • Experimental
    Nuvaxovid

    Participants will receive a single intramuscular injection of Nuvaxovid on Day 1

    Biological: Omicron Subvariant-Based SARS-CoV-2 Recombinant Spike Vaccine Adjuvanted With Matrix-M

Interventions

  • BiologicalOmicron Subvariant-Based SARS-CoV-2 Recombinant Spike Vaccine Adjuvanted With Matrix-M

    Drug page: NVX-CoV2373 adjuvated lipid nanoparticle

    Pharmaceutical form: Sterile suspension for injection Route of administration: Intramuscular injection

    Also known as: Nuvaxovid, NUVAXOVID™

06

What researchers measure

Primary outcomes

  1. Geometric Mean Fold Rise (GMFR) in pseudovirus neutralizing antibody titers (ID50) against the Omicron subvariant included in the vaccine formulation from pre-vaccination to 28 days post-vaccination.

    Superior neutralizing antibody response is defined as a GMFR with a lower bound of the two-sided 95% confidence interval greater than 4.0 within each age cohort.

    Time frame: Day 1 (pre-vaccination) and Day 29 (28 days after vaccination)

Secondary outcomes

  1. Geometric Mean Titers (GMTs) of Pseudovirus Neutralizing Antibodies Against the Omicron Subvariant Included in the Vaccine Formulation

    Pseudovirus neutralizing antibody responses against the Omicron subvariant included in the vaccine formulation will be measured as geometric mean titers (GMTs).

    Time frame: Day 1 (pre-vaccination) and Day 29 (28 days after vaccination)

  2. Seroresponse Rate (SRR) in Pseudovirus Neutralizing Antibody Titers Against the Omicron Subvariant Used in the Vaccine Formulation

    Seroresponse is defined as a pre-vaccination antibody titer below the lower limit of quantitation (LLOQ) and a post-vaccination antibody titer ≥ 4 × LLOQ; at least a 4-fold rise when the pre-vaccination titer is ≥ LLOQ and \< 4 × LLOQ; or at least a 2-fold rise when the pre-vaccination titer is ≥ 4 × LLOQ.

    Time frame: Day 29 (28 days after vaccination)

  3. Presence of Immediate Adverse Events (AEs)

    Number of participants reporting immediate adverse events within 30 minutes following study vaccination.

    Time frame: Within 30 minutes after vaccination on Day 1

  4. Presence of Solicited Injection Site Reactions

    Number of participants reporting solicited injection site reactions during the 8-day period including the day of vaccination.

    Time frame: Day 1 through Day 8

  5. Presence of Solicited Systemic Reactions

    Number of participants reporting solicited systemic reactions during the 8-day period including the day of vaccination.

    Time frame: Day 1 through Day 8

  6. Presence of Unsolicited Adverse Events (AEs)

    Number of participants reporting unsolicited adverse events during the 28-day period including the day of vaccination.

    Time frame: Day 1 through Day 28

  7. Presence of Medically Attended Adverse Events (MAAEs)

    Number of participants reporting medically attended adverse events (MAAEs) during the 28-day period including the day of vaccination.

    Time frame: Day 1 through Day 28

  8. Presence of Related Medically Attended Adverse Events (MAAEs)

    Number of participants reporting medically attended adverse events considered related to the study intervention from Day 29 through the end of the study.

    Time frame: Day 29 through approximately Day 91

  9. Presence of Adverse Events of Special Interest (AESIs)

    Number of participants reporting adverse events of special interest (AESIs) throughout the study. Protocol-defined AESIs include anaphylaxis; myocarditis, pericarditis, or myopericarditis; and new onset or worsening of potential immune-mediated disease.

    Time frame: Day 1 through approximately Day 91

  10. Presence of Serious Adverse Events (SAEs)

    Number of participants reporting serious adverse events (SAEs) throughout the study.

    Time frame: Day 1 through approximately Day 91

  11. Presence of Adverse Events (AEs) Leading to Study Discontinuation

    Number of participants reporting adverse events leading to study discontinuation throughout the study.

    Time frame: Day 1 through approximately Day 91

07

Study locations

20 sites
  • Site #: 8400005
    Fair Oaks, California 95628, United States
  • Site #: 8400002
    Doral, Florida 33172, United States
  • Site #: 8400008
    Atlanta, Georgia 30329, United States
  • Site #: 8400015
    Decatur, Georgia 30030, United States
  • Site #: 8400011
    Melrose Park, Illinois 60160, United States
  • Site #: 8400019
    Sioux City, Iowa 51106, United States
  • Site #: 8400009
    Lenexa, Kansas 66219, United States
  • Site #: 8400001
    Lafayette, Louisiana 70508, United States
  • Site #: 8400003
    New Orleans, Louisiana 70115, United States
  • Site #: 8400024
    Rockville, Maryland 20854, United States
  • Site #: 8400012
    Southfield, Michigan 48076, United States
  • Site #: 8400023
    Grand Island, Nebraska 68803, United States
  • Site #: 8400004
    Omaha, Nebraska 68114, United States
  • Site #: 8400021
    Omaha, Nebraska 68134, United States
  • Site #: 8400016
    Cincinnati, Ohio 45219, United States
  • Site #: 8400007
    Philadelphia, Pennsylvania 19107, United States
  • Site #: 8400018
    Austin, Texas 78750, United States
  • Site #: 8400017
    Frisco, Texas 75033, United States
  • Site #: 8400014
    Houston, Texas 77065, United States
  • Site #: 8400013
    Richmond, Virginia 23226, United States
08

References and documents

Individual participant data

Plan to share: Yes — Qualified researchers may request access to patient level data and related study documents including the clinical study report, study protocol with any amendments, blank case report form, statistical analysis plan, and dataset specifications. Patient level data will be anonymized and study documents will be redacted to protect the privacy of trial participants. Further details on Sanofi's data sharing criteria, eligible studies, and process for requesting access can be found at: https://vivli.org

09

Timeline

3 registry updates since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Oct 2026 (actual). Primary completion is estimated for Nov 2026, 1 month after the start.

Of 44 industry-sponsored phase 4 interventional studies under COVID-19, half reached primary completion within 5 months of starting (the median), counting those still running; a quarter within 3 and three quarters within 12. This study's planned 1 month is below that.

Counting every sponsor, half of 189 studies reached it within 8 months; a quarter within 4 and three quarters within 18.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 30, 2026
First posted
Oct 6, 2026
StartActual
Oct 1, 2026
Primary completionEst.
Nov 26, 2026
CompletionEst.
Jan 27, 2027
Last update
Nov 12, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Not yet recruiting→Recruiting→Active, not recruiting
changed Oct 15, 2026 · changed Nov 12, 2026
Sites
20 sites added — first site in United States
Show 20 added (20 United States)
  • Site #: 8400005 · Fair Oaks, United States
  • Site #: 8400002 · Doral, United States
  • Site #: 8400008 · Atlanta, United States
  • Site #: 8400015 · Decatur, United States
  • Site #: 8400011 · Melrose Park, United States
  • Site #: 8400019 · Sioux City, United States
  • Site #: 8400009 · Lenexa, United States
  • Site #: 8400001 · Lafayette, United States
  • Site #: 8400003 · New Orleans, United States
  • Site #: 8400024 · Rockville, United States
  • Site #: 8400012 · Southfield, United States
  • Site #: 8400023 · Grand Island, United States
  • Site #: 8400004 · Omaha, United States
  • Site #: 8400021 · Omaha, United States
  • Site #: 8400016 · Cincinnati, United States
  • Site #: 8400007 · Philadelphia, United States
  • Site #: 8400018 · Austin, United States
  • Site #: 8400017 · Frisco, United States
  • Site #: 8400014 · Houston, United States
  • Site #: 8400013 · Richmond, United States
Oct 15, 2026
Start date
Oct 2, 2026→Oct 1, 2026 (actual)
Oct 15, 2026
Enrollment
660 (estimated)→669 (actual)
Nov 12, 2026
Registered
First appeared on the registry
Oct 6, 2026
Show all 3 updates
  1. Nov 12, 2026
    Recruiting→Active, not recruiting
    Enrollment 660 (estimated)→669 (actual)
    + 3 other changes: verification date, contact details and site details
  2. Oct 15, 2026
    Not yet recruiting→Recruiting
    20 sites added — first site in United States
    Show 20 added (20 United States)
    • Site #: 8400005 · Fair Oaks, United States
    • Site #: 8400002 · Doral, United States
    • Site #: 8400008 · Atlanta, United States
    • Site #: 8400015 · Decatur, United States
    • Site #: 8400011 · Melrose Park, United States
    • Site #: 8400019 · Sioux City, United States
    • Site #: 8400009 · Lenexa, United States
    • Site #: 8400001 · Lafayette, United States
    • Site #: 8400003 · New Orleans, United States
    • Site #: 8400024 · Rockville, United States
    • Site #: 8400012 · Southfield, United States
    • Site #: 8400023 · Grand Island, United States
    • Site #: 8400004 · Omaha, United States
    • Site #: 8400021 · Omaha, United States
    • Site #: 8400016 · Cincinnati, United States
    • Site #: 8400007 · Philadelphia, United States
    • Site #: 8400018 · Austin, United States
    • Site #: 8400017 · Frisco, United States
    • Site #: 8400014 · Houston, United States
    • Site #: 8400013 · Richmond, United States
    Start date Oct 2, 2026→Oct 1, 2026 (now actual)
    + 2 other changes: verification date and references
  3. Oct 6, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07861542
Lead sponsor
Sanofi
Responsible party
Sponsor
First posted
Oct 6, 2026
Start date
Oct 1, 2026
Primary completion
Nov 26, 2026 (estimated)
Completion
Jan 27, 2027 (estimated)
Last update
Nov 12, 2026

Study contacts

Clinical Sciences & Operations Study Director
study director · Sanofi

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: NVX-CoV2373 adjuvated lipid nanoparticle

Start the discussion